0
Research Letters |

Critical Role of PINK1 in Regulating Parkin Protein Levels In Vivo FREE

Yeun Su Choo, PhD; Chengyuan Tang; Zhuohua Zhang, PhD
[+] Author Affiliations

Author Affiliations: Sanford-Burnham Medical Research Institute, La Jolla, California (Drs Choo and Zhang and Mr Tang); and State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China (Dr Zhang and Mr Tang).


Arch Neurol. 2011;68(5):684-686. doi:10.1001/archneurol.2011.95.
Text Size: A A A
Published online

Mutations in parkin and phosphatase and tensin homolog–induced putative kinase 1 (PINK1) are individually associated with recessive familial forms of Parkinson disease (PD). Parkin is an E3 ligase that promotes ubiquitination of a number of substrates, including itself. In Drosophila, parkin plays essential roles in PINK1-mediated mitochondrial morphology and functions.1,2 We have recently shown that parkin, PINK1, and DJ-1 form an ubiquitin E3 ligase complex (the PPD complex) in which PINK1 increases parkin's ligase activity.3 Parkin levels are dependent inversely on PINK1 levels in cultured mammalian cells.3,4 PINK1 is required for parkin E3 ligase activity during stress conditions. However, regulation of parkin by PINK1 during physiological conditions in mammalian cells remains to be addressed. Here, we demonstrate that parkin levels are increased in PINK1-deficient mouse brains, suggesting that PINK1 plays a critical role in regulating parkin E3 ligase activity and, subsequently, its degradation in vivo.

The parkin-, and PINK1-deficient C57BL/6 mouse lines were generated previously.3,5 All animal procedures were approved by our Institutional Animal Care and Usage Committees. The mouse genotypes were determined by polymerase chain reaction.3,5 Age and sex-matched parkin-deficient (n = 5), wild-type (n = 7), and PINK1-deficient (n = 6) mice were sacrificed (FigureeFigure). Whole-brain lysates were prepared using 2% sodium dodecyl sulfate buffer.3 We separated 25 μg of lysate proteins on 4% to 20% Tris-Glycine gels and immunoblotted with anti-p38/JTV-1 (1:1000 dilution; Proteintech Group, Inc, Chicago, Illinois), anti-α synuclein (1:1000 dilution; Cell Signaling Technology, Inc, Danvers, Massachusetts), anti-parkin, and anti-actin (1:2000 dilution; Sigma-Aldrich, St Louis, Missouri) antibodies. The ratio of parkin or p38/JTV-1 to actin was quantified using ImageJ and analyzed with the unpaired t test with Welch's correction using GraphPad Prism 5 (GraphPad Software, Inc, La Jolla, California).

Place holder to copy figure label and caption
Figure.

Parkin and p38/JTV-1 levels in parkin-deficient (parkin KO), wild-type (WT), and PINK1-deficient (PINK1 KO) mouse brains. A, Immunoblotting is shown. Unlike parkin or p38/JTV-1, α-synuclein, another Parkinson disease–related protein, does not show any notable difference in its level between parkin-deficient and wild-type mouse brains. B, Mice genotyping is shown. C, Quantification of normalized parkin level is shown (* P = .01, 2-tailed). D, Quantification of normalized p38/JTV-1 level is shown (* P = .03, 1-tailed).

Graphic Jump Location

To comprehend the in vivo function and interaction of mammalian parkin and PINK1, we examined parkin levels in the brains of wild-type, parkin-deficient, and PINK1-deficient mice. As shown in the Figure, A, parkin is undetectable in parkin-deficient mouse brains. In contrast, the steady-state level of parkin is significantly elevated in PINK1-deficient brains compared with those in wild-type brains (P = .01). The increased detection of parkin in PINK1-deficient mouse brains was not notably affected by age or sex (eFigure). The results suggest that PINK1 plays a critical role in regulating parkin levels in vivo. One potential explanation for the increased parkin protein in PINK1-deficient brains is that parkin's ubiquitin E3 ligase activity is reduced without PINK1.3 To address this hypothesis, we examined levels of p38/JTV-1, another parkin substrate, in these samples. Consistent with a previous article,6 our results revealed increased p38/JTV-1 levels in parkin-deficient mouse brains compared with wild-type mouse brains. In addition, p38/JTV-1 levels were shown to be greater in PINK1-deficient brains than in wild-type brains (P = .03, 1-tailed) (Figure, D) despite an increased level of parkin in PINK1-deficient brains. Quantitative real-time polymerase chain reaction indicates that parkin messenger RNA levels remain similar in brains of wild-type and PINK1-deficient mice (data not shown). The results suggest that PINK1 plays a critical role in the degradation of parkin substrates parkin and p38/JTV-1.

We have shown in this study that the steady-state level of parkin protein is regulated by PINK1 in vivo. The increased parkin level in PINK1-deficient mouse brains is likely caused by suppressed parkin E3 ligase activity in the absence of PINK1. Consistent with this notion, the level of p38/JTV-1 is also increased in brains of both parkin- and PINK1-deficient mice. Furthermore, the results of this study support our previous finding that parkin/PINK1/DJ-1 complex functions as an E3 ligase complex to promote degradation of parkin substrates and that PINK1 plays a crucial role in regulating parkin E3 ligase activity.3 p38/JTV-1 is a parkin substrate shown to accumulate in the ventral midbrain/hindbrain of parkin-deficient mice.6 By showing an increase in p38/JTV-1 levels in brains of an additional line of parkin-deficient mice, we provide further supporting evidence that p38/JTV-1 is an authentic parkin substrate. Additionally, the results suggest that parkin is the substrate of itself in vivo. Parkin and PINK1 interact in Drosophila and mammalian cells to either maintain mitochondrial function or promote degradation of unfolded proteins via the ubiquitin proteasomal pathway.13 The results of this study offer in vivo evidence to support parkin/PINK1 E3 ligase function in mammalian cells.

Correspondence: Dr Zhang, Sanford-Burnham Medical Research Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037 (benzz@sanfordburnham.org).

Accepted for Publication: December 29, 2010.

Author Contributions:Study concept and design: Choo, Tang, and Zhang. Acquisition of data: Choo. Analysis and interpretation of data: Choo and Zhang. Drafting of the manuscript: Choo. Critical revision of the manuscript for important intellectual content: Tang and Zhang. Statistical analysis: Choo. Obtained funding: Choo and Zhang. Administrative, technical, and material support: Tang and Zhang. Study supervision: Zhang.

Financial Disclosure: None reported.

Funding/Support: This study was supported by National Institute of Health grants RO1 NS057289 and PO1 ES016738 (Dr Zhang); California Institute for Regenerative Medicine grants RL1-00682-1 (Dr Zhang); Chinese Natural Science Foundation grants (Dr Zhang); and the American Parkinson Disease Association (Dr Choo).

Additional Contributions: We thank Rena Baek, PhD, for editing the manuscript.

Clark  IEDodson  MWJiang  C  et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006;441 (7097) 1162- 1166
PubMed
Park  JLee  SBLee  S  et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006;441 (7097) 1157- 1161
PubMed
Xiong  HWang  DChen  L  et al.  Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009;119 (3) 650- 660
PubMed
Rakovic  AGrünewald  ASeibler  P  et al.  Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010;19 (16) 3124- 3137
PubMed
Goldberg  MSFleming  SMPalacino  JJ  et al.  Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003;278 (44) 43628- 43635
PubMed
Ko  HSvon Coelln  RSriram  SR  et al.  Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 2005;25 (35) 7968- 7978
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Parkin and p38/JTV-1 levels in parkin-deficient (parkin KO), wild-type (WT), and PINK1-deficient (PINK1 KO) mouse brains. A, Immunoblotting is shown. Unlike parkin or p38/JTV-1, α-synuclein, another Parkinson disease–related protein, does not show any notable difference in its level between parkin-deficient and wild-type mouse brains. B, Mice genotyping is shown. C, Quantification of normalized parkin level is shown (* P = .01, 2-tailed). D, Quantification of normalized p38/JTV-1 level is shown (* P = .03, 1-tailed).

Graphic Jump Location

Tables

References

Clark  IEDodson  MWJiang  C  et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006;441 (7097) 1162- 1166
PubMed
Park  JLee  SBLee  S  et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006;441 (7097) 1157- 1161
PubMed
Xiong  HWang  DChen  L  et al.  Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009;119 (3) 650- 660
PubMed
Rakovic  AGrünewald  ASeibler  P  et al.  Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010;19 (16) 3124- 3137
PubMed
Goldberg  MSFleming  SMPalacino  JJ  et al.  Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003;278 (44) 43628- 43635
PubMed
Ko  HSvon Coelln  RSriram  SR  et al.  Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 2005;25 (35) 7968- 7978
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles